Cargando…
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
PURPOSE OF REVIEW: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088198/ https://www.ncbi.nlm.nih.gov/pubmed/33932165 http://dx.doi.org/10.1007/s11926-021-01008-8 |
_version_ | 1783686802470600704 |
---|---|
author | Erkan, Doruk Sciascia, Savino Bertolaccini, Maria Laura Cohen, Hannah |
author_facet | Erkan, Doruk Sciascia, Savino Bertolaccini, Maria Laura Cohen, Hannah |
author_sort | Erkan, Doruk |
collection | PubMed |
description | PURPOSE OF REVIEW: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions. RECENT FINDINGS: APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. SUMMARY: APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients. |
format | Online Article Text |
id | pubmed-8088198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-80881982021-05-03 Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update Erkan, Doruk Sciascia, Savino Bertolaccini, Maria Laura Cohen, Hannah Curr Rheumatol Rep Antiphospholipid Syndrome (S Zuily, Section Editor) PURPOSE OF REVIEW: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions. RECENT FINDINGS: APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. SUMMARY: APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients. Springer US 2021-05-01 2021 /pmc/articles/PMC8088198/ /pubmed/33932165 http://dx.doi.org/10.1007/s11926-021-01008-8 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021, corrected publication 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Antiphospholipid Syndrome (S Zuily, Section Editor) Erkan, Doruk Sciascia, Savino Bertolaccini, Maria Laura Cohen, Hannah Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update |
title | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update |
title_full | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update |
title_fullStr | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update |
title_full_unstemmed | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update |
title_short | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update |
title_sort | antiphospholipid syndrome alliance for clinical trials and international networking (aps action): 10-year update |
topic | Antiphospholipid Syndrome (S Zuily, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088198/ https://www.ncbi.nlm.nih.gov/pubmed/33932165 http://dx.doi.org/10.1007/s11926-021-01008-8 |
work_keys_str_mv | AT erkandoruk antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate AT sciasciasavino antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate AT bertolaccinimarialaura antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate AT cohenhannah antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate AT antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate |